No products in the cart
Cardiogen peptides are Synthesized and Lyophilized in the USA.
Discount per Quantity
|Quantity||5 - 9||10 +|
FREE - 30ml bottle of bacteriostatic water
(Required for reconstitution)
FREE - USPS priority shipping
What Is Cardiogen Peptide?
Cardiogen is a cardiovascular bioregulator peptide complex. It is a dietary additive with a synthesized heart peptide. It alternates the heart functions to normal by causing a decrease in its peptide deficiency and restores the synthesis of protein in the heart cells.
The results obtained from research show that its primary functions are on fibroblasts, cells responsible for scar formation, and tissue repair throughout the body.
This peptide focuses on the cardiovascular system, hence the name. Through the synergistic peptide, it enhances the effects and advantages of some standard therapies, which would amount to long-term outcomes even as it reduces side effects.
The research on rat models show that cardiogen can multiply apoptosis rates in tumor cells.
Molecular Formula: C18H31N7O9
Molecular Weight: 489.5 g/mol
Peptide complex AKS-K (peptide-linked amino acids): Glutamic, aspartic, alanine, arginine. Inactive ingredients: Microcrystalline cellulose (E460), beetroot sugar, lactose, starch, Tween-80, 60 capsules.
PubChem: CID 11583989
Cardiogen and the Heart
Cardiogen stimulates the proliferation of cardiomyocytes, reduces the growth and development of fibroblasts and causes a reduction in the formation of scars, and allows for improved long-term outcomes in cardiac remodeling that can result in congestive cardiac failure.
Moreover, it shows that cardiogen can cause a decrease in the expression of the p53 protein, which will result in a reduced rate of apoptosis.
In older adults, cardiogen is used to treat hypertension, heart failure, attacks of angina pectoris, coronary heart disease, myocardial hypertrophy, myocarditis, and myocardiodystrophy. It can also cause an increase in stamina under heavy loads and adverse environmental factors (athletes, submarines, and others).
The treatment and prevention of cardiovascular diseases via cardiogen allows patients to attain active longevity and decrease the risk of pathologies in the heart muscle.
The Effects of Cardiogen on Prostate
Cardiogen, along with several peptides, can cause positive changes in the expression of signaling factors in the fibroblasts of proteins. Signaling factors are responsible for fostering the development and succession of prostate cancer.
In aging and senescent fibroblasts, these signaling factors are altered. This alteration explains why prostate cancer is ever-present in older men but is rarely evident in younger men.
These studies prove that cardiogen plays a vital role in bringing these signaling factors to normal levels to be identical or even better than what is in young cell cultures. These studies show promise for detailed development of methods of peptides’ regulation of aging and age-correction of violations of functioning of the prostate gland. As a result, cardiogen can be an essential substance in both the prevention of prostate cancer and managing the succession of prostate cancer development.
Effects of Cardiogen on Cancer
Research shows that cardiogen is an effective reductant of apoptosis in the cardiomyocytes via decreasing the expression of p53 and that it can have an opposite effect in tumor cells.
The tumor-modifying effect of cardiogen, which was experimented on rat models with M-1 sarcoma, proved that apoptosis on tumor cells was higher than usual and beyond control. It also proved that is is due to the development of necrotic hemorrhagic and the enhancement of tumor cell apoptosis.
This proliferative activity shows that the tumor growth inhibition is not due to the direct effect of a cytostatic drug on the tumor. Morphology has proven that it may be due to a particular mechanism of action of the peptide.
This process may be the case for some tumor cells because of their increased and atypical vascular supply. Due to this, the use of cardiogen may come in handy in treating some cancer. If it increases the action of standard cancer treatments, the peptide might be used as a potent additive to the armaments for fighting cancer.
In Russia, the Cardiogen 20mg will soon be considered a potential option in treating sarcoma. This result is a consequence of the research extensively carried out by Doctors Levdik and Knyazkin, who worked with Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. This research is affiliated with the Russian Academy of Medical Sciences.
Cardiogen 20mg is intended as a research chemical only, and the least experimented with compared to the other bioregulators but indicates its potency on multiple body issues – the heart and prostate. Cardiogen proves to be beneficial in treating certain types of cancers – sarcoma in contrast.
The benefits of this peptide are effective in heart attack, chronic heart failure, and hypertension but in a symbiotic manner with established treatments.
Cardiogen doesn’t have identifiable side effects and doesn’t cause addiction or allergic reactions. Although, contraindications might be evident in intolerable individuals, pregnancy, and lactation.
Rat and mice models exhibit minimal side effects and good oral and excellent subcutaneous bioavailability. The specified dosage per kg in mice isn’t scaled down to be the same in humans.
- Fedoreyeva, L. I., Kireev, I. I., Khavinson, V. K.h, & Vanyushin, B. F. (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry. Biokhimiia, 76(11), 1210–1219. https://doi.org/10.1134/S0006297911110022
- Chalisova NI, Lesniak VV, Balykina NA, et al. [The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats]. Advances in Gerontology = Uspekhi Gerontologii. 2009 ;22(3):409-413. PMID: 20210190.
- Kheĭfets OV, Poliakova VO, Kvetnoĭ IM. [Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging]. Advances in Gerontology = Uspekhi Gerontologii. 2010 ;23(1):68-70. PMID: 20586252.
- Zakutskiĭ, A. N., Chalisova, N. I., & Subbotina, T. F. (2008). Bioorganicheskaia khimiia, 34(2), 149–159. https://doi.org/10.1134/s1068162008020015
- Levdik, N. V., & Knyazkin, I. V. (2009). Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. Bulletin of experimental biology and medicine, 148(3), 433–436. https://doi.org/10.1007/s10517-010-0730-9
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.